Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma
Non Small Cell Lung Cancer
Malignant Peripheral Nerve Sheath Tumors
Solid Tumor
Pancreatic Adenocarcinoma
Advanced Solid Tumor

Interventions

DRUG: MRTX1719

Sponsor

Bristol-Myers Squibb